Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy

Norisato Hashimoto, Kenji Yokoyama, Ken Sadahira, Tomoki Ueda, Yuiko Tsukada, Shinichiro Okamoto

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Bortezomib (BOR) is an effective drug for the treatment of multiple myeloma and BOR-induced peripheral neuropathy (BIPN) is a major adverse event. BIPN tends to occur after two or three cycles of treatment (late-onset BIPN), but may occur during the first treatment cycle (early-onset BIPN). BIPN severity was retrospectively assessed and graded in 48 patients with relapsed or refractory multiple myeloma treated with BOR for the first time between June 2007 and February 2011 at Keio University Hospital. PN grade 2 or higher occurring within the first cycle of BOR was defined as early-onset severe BIPN. Early-onset severe BIPN occurred in 13 patients. Concomitant use of itraconazole [ITCZ: odds ratio (OR) 29.14 (3.02-281.56), p = 0.004] and a proton pump inhibitor [OR 9.00 (1.05-77.1), p = 0.04] were identified by univariate analysis, as risk factors for developing early-onset severe BIPN. Based on multivariate analysis, concomitant use of ITCZ was the only significant risk factor for developing early-onset severe BIPN [OR 19.00 (1.89-190.96), p = 0.01]. Concomitant use of ITCZ with BOR significantly increased the incidence of early-onset severe BIPN in our study population, suggesting that administration of ITCZ in patients receiving BOR should be avoided.

Original languageEnglish
Pages (from-to)758-763
Number of pages6
JournalInternational Journal of Hematology
Volume96
Issue number6
DOIs
Publication statusPublished - 2012 Dec

Fingerprint

Itraconazole
Peripheral Nervous System Diseases
Odds Ratio
Multiple Myeloma
Bortezomib
Proton Pump Inhibitors
Therapeutics
Multivariate Analysis

Keywords

  • Bortezomib
  • Itraconazole
  • Multiple myeloma
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Hematology

Cite this

Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. / Hashimoto, Norisato; Yokoyama, Kenji; Sadahira, Ken; Ueda, Tomoki; Tsukada, Yuiko; Okamoto, Shinichiro.

In: International Journal of Hematology, Vol. 96, No. 6, 12.2012, p. 758-763.

Research output: Contribution to journalArticle

Hashimoto, Norisato ; Yokoyama, Kenji ; Sadahira, Ken ; Ueda, Tomoki ; Tsukada, Yuiko ; Okamoto, Shinichiro. / Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy. In: International Journal of Hematology. 2012 ; Vol. 96, No. 6. pp. 758-763.
@article{68b2e32dd47240dbb64be34fa7f018b0,
title = "Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy",
abstract = "Bortezomib (BOR) is an effective drug for the treatment of multiple myeloma and BOR-induced peripheral neuropathy (BIPN) is a major adverse event. BIPN tends to occur after two or three cycles of treatment (late-onset BIPN), but may occur during the first treatment cycle (early-onset BIPN). BIPN severity was retrospectively assessed and graded in 48 patients with relapsed or refractory multiple myeloma treated with BOR for the first time between June 2007 and February 2011 at Keio University Hospital. PN grade 2 or higher occurring within the first cycle of BOR was defined as early-onset severe BIPN. Early-onset severe BIPN occurred in 13 patients. Concomitant use of itraconazole [ITCZ: odds ratio (OR) 29.14 (3.02-281.56), p = 0.004] and a proton pump inhibitor [OR 9.00 (1.05-77.1), p = 0.04] were identified by univariate analysis, as risk factors for developing early-onset severe BIPN. Based on multivariate analysis, concomitant use of ITCZ was the only significant risk factor for developing early-onset severe BIPN [OR 19.00 (1.89-190.96), p = 0.01]. Concomitant use of ITCZ with BOR significantly increased the incidence of early-onset severe BIPN in our study population, suggesting that administration of ITCZ in patients receiving BOR should be avoided.",
keywords = "Bortezomib, Itraconazole, Multiple myeloma, Peripheral neuropathy",
author = "Norisato Hashimoto and Kenji Yokoyama and Ken Sadahira and Tomoki Ueda and Yuiko Tsukada and Shinichiro Okamoto",
year = "2012",
month = "12",
doi = "10.1007/s12185-012-1224-5",
language = "English",
volume = "96",
pages = "758--763",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy

AU - Hashimoto, Norisato

AU - Yokoyama, Kenji

AU - Sadahira, Ken

AU - Ueda, Tomoki

AU - Tsukada, Yuiko

AU - Okamoto, Shinichiro

PY - 2012/12

Y1 - 2012/12

N2 - Bortezomib (BOR) is an effective drug for the treatment of multiple myeloma and BOR-induced peripheral neuropathy (BIPN) is a major adverse event. BIPN tends to occur after two or three cycles of treatment (late-onset BIPN), but may occur during the first treatment cycle (early-onset BIPN). BIPN severity was retrospectively assessed and graded in 48 patients with relapsed or refractory multiple myeloma treated with BOR for the first time between June 2007 and February 2011 at Keio University Hospital. PN grade 2 or higher occurring within the first cycle of BOR was defined as early-onset severe BIPN. Early-onset severe BIPN occurred in 13 patients. Concomitant use of itraconazole [ITCZ: odds ratio (OR) 29.14 (3.02-281.56), p = 0.004] and a proton pump inhibitor [OR 9.00 (1.05-77.1), p = 0.04] were identified by univariate analysis, as risk factors for developing early-onset severe BIPN. Based on multivariate analysis, concomitant use of ITCZ was the only significant risk factor for developing early-onset severe BIPN [OR 19.00 (1.89-190.96), p = 0.01]. Concomitant use of ITCZ with BOR significantly increased the incidence of early-onset severe BIPN in our study population, suggesting that administration of ITCZ in patients receiving BOR should be avoided.

AB - Bortezomib (BOR) is an effective drug for the treatment of multiple myeloma and BOR-induced peripheral neuropathy (BIPN) is a major adverse event. BIPN tends to occur after two or three cycles of treatment (late-onset BIPN), but may occur during the first treatment cycle (early-onset BIPN). BIPN severity was retrospectively assessed and graded in 48 patients with relapsed or refractory multiple myeloma treated with BOR for the first time between June 2007 and February 2011 at Keio University Hospital. PN grade 2 or higher occurring within the first cycle of BOR was defined as early-onset severe BIPN. Early-onset severe BIPN occurred in 13 patients. Concomitant use of itraconazole [ITCZ: odds ratio (OR) 29.14 (3.02-281.56), p = 0.004] and a proton pump inhibitor [OR 9.00 (1.05-77.1), p = 0.04] were identified by univariate analysis, as risk factors for developing early-onset severe BIPN. Based on multivariate analysis, concomitant use of ITCZ was the only significant risk factor for developing early-onset severe BIPN [OR 19.00 (1.89-190.96), p = 0.01]. Concomitant use of ITCZ with BOR significantly increased the incidence of early-onset severe BIPN in our study population, suggesting that administration of ITCZ in patients receiving BOR should be avoided.

KW - Bortezomib

KW - Itraconazole

KW - Multiple myeloma

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84875271124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875271124&partnerID=8YFLogxK

U2 - 10.1007/s12185-012-1224-5

DO - 10.1007/s12185-012-1224-5

M3 - Article

C2 - 23179905

AN - SCOPUS:84875271124

VL - 96

SP - 758

EP - 763

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 6

ER -